Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

703 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Global AIDS Response Is At A Precarious Point: UN Report

    On July 18, 2018, UNAIDS released a report titled "Miles to go—closing gaps, breaking barriers, righting injustices " as a part of global AIDS update report 2018.
    GlobalFood, Drugs, Healthcare, Life Sciences
    S&A Law Offices
    S&A Law Offices
  • Article

    Competition Monthly Newsletter - July 2025

    Welcome to the July 2025 edition of Phoenix Legal's Competition Monthly. This issue captures key developments in the antitrust and competition space during the last calendar month.
    IndiaAntitrust/Competition Law
    Phoenix Legal
    Phoenix Legal
Article

Note On CCI's Report On The Pharmaceutical Sector

Key findings and observations from a market analysis conducted by the Competition Commission of India (CCI) were revealed on November 18, 2021.
IndiaAntitrust/Competition Law
Khurana & Khurana, Advocates and IP Attorneys
Khurana & Khurana, Advocates and IP Attorneys
  • Article

    Changes To The Regulatory Framework For Clinical Trials In India

    The total cost for bringing a new prescription drug to market is about USD 2 to 3 billion (DiMasi et al.). A significant portion of this cost is incurred in conducting clinical trials.
    IndiaFood, Drugs, Healthcare, Life Sciences
    Obhan Mason
    Obhan Mason
  • Article

    Karnataka's Proposed Good Samaritan And Medical Professional Protection Rules, 2026: A Comprehensive Legal Framework For Emergency Medical Assistance

    The Government of Karnataka has taken a significant step towards enhancing emergency medical care and protecting Good Samaritans through the promulgation of comprehensive rules under the Karnataka Good Samaritan...
    IndiaFood, Drugs, Healthcare, Life Sciences
    IndiaLaw LLP
    IndiaLaw LLP
  • Article

    Salient Features Of The National Nursing And Midwifery Commission Act, 2023

    On August 12, 2023, the National Nursing and Midwifery Commission Act, 2023 ("NNMC"), was given the assent of the President. The NNMC brings significant legislative reform in the sector...
    IndiaFood, Drugs, Healthcare, Life Sciences
    Dentons
    Dentons
  • Article

    When "Slightest Possibility" Meets Burden Of Proof: Delhi High Court's Bevatas v. Bevetex Ruling

    In a recent ruling concerning trademark infringement in pharmaceuticals, a Division Bench of the Delhi High Court set aside a permanent injunction that restrained Intas Pharmaceuticals from selling its anti-cancer drug under the mark BEVATAS. The decision is significant for two reasons. First, it pushes back against the principle of “even the slightest possibility of confusion” which is standard in pharmaceutical cases due to the Supreme Court’s ruling in Cadila Healthcare (2001).
    IndiaFood, Drugs, Healthcare, Life Sciences
    S.S. Rana & Co.
    S.S. Rana & Co.
  • Article

    When Procedure Fails, The Constitution Steps In: Bombay High Court Grants Full Reimbursement For Heart Surgery

    In a remarkable judgment in Anirudh Prataprai Nansi v. Union of India1, a Division Bench of the Bombay High Court comprising Justices G.S. Kulkarni and Advait M. Sethna highlighted...
    IndiaGovernment, Public Sector
    IndiaLaw LLP
    IndiaLaw LLP
  • Article

    How Has The IPR In The Health-Tech Industry Boomed Since Covid-19?

    The COVID-19 pandemic has significantly impacted various sectors, and the health-Tech industry has experienced its fair share of challenges and transformations.
    IndiaIntellectual Property
    Photon legal
    Photon legal
  • Article

    Legal Insights On Pharma Trademark Similarity And Confusion

    Macleods Pharmaceuticals Ltd. (Macleods Pharma), invoking its rights in the previously used trademark ‘ALRISTA', filed an infringement suit...
    IndiaIntellectual Property
    S.S. Rana & Co.
    S.S. Rana & Co.
  • Article

    Medicines, Monopolies, And Justice: India’s Fight For Fair Patents

    The importance of these decisions lies in their widespread impact. Countries like Brazil and South Africa have implemented India's approach in their own healthcare challenges. Fundamentally, this issue extends beyond patents, touching on the principles of fairness, dignity, and justice in the realm of global health.
    IndiaIntellectual Property
    Khurana & Khurana, Advocates and IP Attorneys
    Khurana & Khurana, Advocates and IP Attorneys
  • Article

    Publici Juris – In Pharma Products

    Publici juris" is a Latin word, and in the legal parlance, means, "of public right". The term signifies a thing or a right that is open and exercisable by all persons. It designates things that belong to the entire community, and not to any private party.
    IndiaIntellectual Property
    Lex Orbis
    Lex Orbis
  • Article

    Trips Plus And Biodrugs: Imperative Poise Between IP Fundamentalism And Access To Biodrugs

    It encompasses vaccines, insulin, monoclonal antibodies, therapeutic proteins and gene therapy products.
    IndiaIntellectual Property
    Khurana & Khurana, Advocates and IP Attorneys
    Khurana & Khurana, Advocates and IP Attorneys
  • Article

    Data Exclusivity - Its Interpretation and India

    The Intellectual Property Regime in India is in the final stages of ensuring compliance with the standards agreed in the World Trade Organization’s Agreement on the Trade Related Aspects of Intellectual Property Rights (‘TRIPS’).
    IndiaInternational Law
    Legally Lawyers
    Legally Lawyers
  • Article

    Regulating The Price Of Health: A Legal Analysis Of India’s 2026 Drug Ceiling Price Notification

    On March 25, 2026, the National Pharmaceutical Pricing Authority (NPPA), operating under the aegis of the Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), Government of India...
    IndiaFood, Drugs, Healthcare, Life Sciences
    IndiaLaw LLP
    IndiaLaw LLP
  • Article

    COVID-19: A Pandemic, A Force Majeure And A Material Adverse Change

    As another week passed by, the utter state of bewilderment brought by novel coronavirus (COVID-19) pandemic continues to claim lives across the world.
    IndiaCorporate/Commercial Law
    King, Stubb & Kasiva
    King, Stubb & Kasiva
  • Article

    Employer Liability And Employee Suicide–Keeping Workplace Wellness In Check

    An individual's suicide casts long shadows of grief and confusion across families, friendships and the entire society. The ripple effects of suicide do not end with the immediate loss...
    IndiaEmployment and HR
    CMS INDUSLAW
    CMS INDUSLAW
  • Article

    Force Majeure And Coronavirus: Frequently Asked Questions - Part 2

    In this Part 2, we have attempted to answer some of the questions which businesses are asking concerning their ability
    IndiaEmployment and HR
    LexCounsel
    LexCounsel
  • Article

    Air Pollution In Delhi: Hidden Causes

    Diwali, the festival of lights, is a joyous occasion celebrated with enthusiasm across India.
    IndiaEnvironment
    S.S. Rana & Co.
    S.S. Rana & Co.
  • Article

    A Drug Pill Which Could Change How Medicines Will Be Priced Forever

    Assume your doctor prescribes a drug to you. The brand-name version costs $300 a month. Another generic drug on the other hand will cost $30. As most people would, you would also purchase the cheaper one. That generic cheaper bottle exists as a result of a delicate legal balancing act, an act that the U.S. Supreme Court is now reconsidering in a case that could change pharmaceutical competition for decades.
    IndiaFood, Drugs, Healthcare, Life Sciences
    LegaLogic
    LegaLogic
  • Showing 441–460 of 703 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics